# Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT07408609** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 114 (estimated)

## Conditions studied

- Gastric or Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Low Dose Radiotherapy Combined with Tislelizumab and Chemotherapy
- **DRUG:** Chemotherapeutic Agent
- **DEVICE:** low-dose radiotherapy

## Key facts

- **NCT ID:** NCT07408609
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-26
- **Primary completion:** 2029-02-20
- **Final completion:** 2031-02-20
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07408609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07408609, "Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07408609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*